-+ 0.00%
-+ 0.00%
-+ 0.00%

Regentis Biomaterials posts investor deck on GelrinC off-the-shelf knee cartilage repair hydrogel

PUBT·08/12/2026 11:58:10
Listen to the news
Regentis Biomaterials posts investor deck on GelrinC off-the-shelf knee cartilage repair hydrogel
  • Regentis outlined GelrinC, an acellular PEG hydrogel implant positioned as an off-the-shelf option for knee cartilage repair.
  • U.S. opportunity framed at about 472,500 cartilage-damage procedures annually, implying an estimated USD 3 billion addressable market.
  • Phase III pivotal IDE trial targets 80 patients; enrollment completion expected in Q3 2026; PMA submission work expected to start end-2027.
  • Phase II data cited KOOS and VAS improvements about 100% greater than microfracture at 24 months; mean MOCART 88.8 at 24 months.
  • Financing update cited USD 6.5 million gross proceeds in June 2026; European commercialization efforts starting 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.